Feasibility of local or regional delivery has also been shown (intracranial HER2 CAR-NK-92 in recurrent glioblastoma; hepatic–arterial infusion of high-dose autologous NK cells following hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma) with manageable safety and early activity [23,37]. The gene discussed is ERBB2; the disease is glioblastoma.